Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Oric Pharmaceuticals Inc
(NQ:
ORIC
)
9.710
+0.190 (+2.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
277,184
Open
9.770
Bid (Size)
9.150 (1)
Ask (Size)
9.990 (3)
Prev. Close
9.520
Today's Range
9.480 - 10.05
52wk Range
4.900 - 16.65
Shares Outstanding
54,532,614
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Today 16:30 EDT
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
April 19, 2024
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.
Via
Benzinga
Performance
YTD
+6.24%
+6.24%
1 Month
-20.21%
-20.21%
3 Month
-15.71%
-15.71%
6 Month
+43.85%
+43.85%
1 Year
+87.45%
+87.45%
More News
Read More
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
April 15, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) is a Stock Spotlight on 3/1
March 01, 2024
Via
Investor Brand Network
Where ORIC Pharmaceuticals Stands With Analysts
December 13, 2023
Via
Benzinga
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
April 04, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
March 21, 2024
Via
Benzinga
These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results
March 12, 2024
Via
Benzinga
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
March 11, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
March 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
Via
Benzinga
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
February 29, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
February 14, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
MicroMarvel - ORIC Pharmaceutical - Fights Cancer
February 07, 2024
Via
Talk Markets
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
January 31, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
January 22, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Final Boarding Call: 3 Stocks Set for a Sky-High Surge
January 09, 2024
Via
InvestorPlace
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
January 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
December 11, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.